BACKGROUND: Inhibition of leukocyte adhesion can reduce myocardial infarct size in animals. This study was designed to define the safety and efficacy of a recombinant, humanized, monoclonal antibody to the CD18 subunit of the beta2 integrin adhesion receptors (rhuMAb CD18), in reducing infarct size in patients treated with a thrombolytic agent. METHODS AND RESULTS: The Limitation of Myocardial Infarction following Thrombolysis in Acute Myocardial Infarction Study (LIMIT AMI) was a randomized, double-blind, placebo-controlled, multicenter study conducted in 60 centers in the United States and Canada. A total of 394 subjects who presented within 12 hours of symptom onset with ECG findings (ST-segment elevation) consistent with AMI were treated withrecombinant tissue plasminogen activator and were also given an intravenous bolus of 0.5 or 2.0 mg/kg rhuMAb CD18 or placebo. Coronary angiography was performed at 90 minutes, 12-lead ECGs were obtained at baseline, 90, and 180 minutes, and resting sestamibi scans were performed at >/=120 hours. Adjunctive angioplasty and use of glycoprotein IIb/IIIa antiplatelet agents at the time of angiography were discretionary. There were no treatment effects on coronary blood flow, infarct size, or the rate of ECG ST-segment elevation resolution, despite the expected induction of peripheral leukocytosis. A slight trend toward an increase in bacterial infections was observed with rhuMAb CD18 (P=0.33). CONCLUSIONS:RhuMAb CD18 was well tolerated but not effective in modifying cardiac end points.
RCT Entities:
BACKGROUND: Inhibition of leukocyte adhesion can reduce myocardial infarct size in animals. This study was designed to define the safety and efficacy of a recombinant, humanized, monoclonal antibody to the CD18 subunit of the beta2 integrin adhesion receptors (rhuMAb CD18), in reducing infarct size in patients treated with a thrombolytic agent. METHODS AND RESULTS: The Limitation of Myocardial Infarction following Thrombolysis in Acute Myocardial Infarction Study (LIMIT AMI) was a randomized, double-blind, placebo-controlled, multicenter study conducted in 60 centers in the United States and Canada. A total of 394 subjects who presented within 12 hours of symptom onset with ECG findings (ST-segment elevation) consistent with AMI were treated with recombinant tissue plasminogen activator and were also given an intravenous bolus of 0.5 or 2.0 mg/kg rhuMAb CD18 or placebo. Coronary angiography was performed at 90 minutes, 12-lead ECGs were obtained at baseline, 90, and 180 minutes, and resting sestamibi scans were performed at >/=120 hours. Adjunctive angioplasty and use of glycoprotein IIb/IIIa antiplatelet agents at the time of angiography were discretionary. There were no treatment effects on coronary blood flow, infarct size, or the rate of ECG ST-segment elevation resolution, despite the expected induction of peripheral leukocytosis. A slight trend toward an increase in bacterial infections was observed with rhuMAb CD18 (P=0.33). CONCLUSIONS: RhuMAb CD18 was well tolerated but not effective in modifying cardiac end points.
Authors: Tibor Kempf; Alexander Zarbock; Christian Widera; Stefan Butz; Anika Stadtmann; Jan Rossaint; Matteo Bolomini-Vittori; Mortimer Korf-Klingebiel; L Christian Napp; Birte Hansen; Anna Kanwischer; Udo Bavendiek; Gernot Beutel; Martin Hapke; Martin G Sauer; Carlo Laudanna; Nancy Hogg; Dietmar Vestweber; Kai C Wollert Journal: Nat Med Date: 2011-04-24 Impact factor: 53.440
Authors: Chiara Melloni; Sunil V Rao; Thomas J Povsic; Laura Melton; Raymond J Kim; Rakhi Kilaru; Manesh R Patel; Mark Talan; Luigi Ferrucci; Dan L Longo; Edward G Lakatta; Samer S Najjar; Robert A Harrington Journal: Am Heart J Date: 2010-11 Impact factor: 4.749
Authors: Marcin Bujak; Hyuk Jung Kweon; Khaled Chatila; Na Li; George Taffet; Nikolaos G Frangogiannis Journal: J Am Coll Cardiol Date: 2008-04-08 Impact factor: 24.094
Authors: C Michael Gibson; Daniel Frisch; Sabina A Murphy; Steven G Gourlay; Raymond Gibbons; Kenneth W Baran; Michel Nguyen; Sebastian Palmeri; Hal V Barron Journal: J Thromb Thrombolysis Date: 2002-04 Impact factor: 2.300
Authors: C Michael Gibson; James A de Lemos; Sabina A Murphy; Susan J Marble; Kent W Dauterman; Andrew Michaels; Hal V Barron; Elliott M Antman Journal: J Thromb Thrombolysis Date: 2002-12 Impact factor: 2.300